Zura Bio (ZURA) said Monday that it has begun a phase 2 study evaluating tibulizumab as a treatment for adult patients with systemic sclerosis.
The immunology company said the study includes a 24-week efficacy period and a 28-week open-label extension. It also said the primary endpoint of the trial is the modified Rodnan Skin Score.
Shares of Zura Bio were down 1.8% in recent trading.
Price: 2.24, Change: -0.04, Percent Change: -1.75
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。